All In Biotech

Free tool

FAERS Monitor: Astagraf Xl

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204096 or its brand name (Astagraf Xl, Tacrolimus). Reports on generic versions are filed under their own applications.

Reports

353

Serious

192

54% of reports

Hospitalization

99

Death reported

40

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death27
  • inappropriate schedule of drug administration20
  • diarrhoea15
  • hospitalisation15
  • off label use14
  • malaise13
  • pneumonia13
  • nausea11
  • treatment noncompliance11
  • kidney transplant rejection10
  • pyrexia10
  • vomiting10
  • immunosuppressant drug level decreased9
  • tremor9
  • asthenia7

Reports by year received

View as table
YearReports
20111
20131
201446
201557
201659
201757
201845
201910
202013
20216
202211
202312
202421
20256
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,806 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
immunosuppressant drug level decreasedSignal9450.7235.93,574
kidney transplant rejectionSignal10124.467.51,102
inappropriate schedule of drug administrationSignal2016.810.9282
treatment noncomplianceSignal1112.06.7100
hospitalisationSignal155.83.556
tremorSignal93.21.712
pneumoniaSignal132.41.49
death271.91.310
malaise131.81.04
pyrexia101.70.92
diarrhoea151.40.81
vomiting101.30.70
asthenia71.10.50
off label use141.00.60
nausea110.80.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.